GlassScriptPhysician profile
Kirsten E Dickinson
NPI 1366893752
$5,598.92
in general payments reported to CMS, 2019-2025
28 companies · $2,296 in 2025
The $2,296 reported for 2025 was more than what 79% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $109 · 2021: $116 · 2022: $702 · 2023: $1,148 · 2024: $1,103 · 2025: $2,296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,375 · Education: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,375.38 |
| Education | $171.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $693.00 | 2022-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $685.70 | 2022-2025 | Tremfya |
| Ucb, INC. | $656.61 | 2023-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $450.27 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Sun Pharmaceutical Industries INC. | $354.25 | 2020-2025 | Ilumya, Blu-U, Odomzo |
| E.R. Squibb & Sons, L.L.C. | $294.88 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $293.35 | 2021-2025 | Libtayo, Dupixent |
| Dermavant Sciences, INC. | $253.95 | 2023-2024 | Vtama |
| Amgen INC. | $240.59 | 2022-2025 | Otezla, Otezla |
| Merz North America, INC. | $209.42 | 2022 | |
| Novartis Pharmaceuticals Corporation | $187.55 | 2022-2025 | |
| Genzyme Corporation | $171.64 | 2019-2024 | |
| Incyte Corporation | $168.48 | 2022-2025 | Opzelura |
| Galderma Laboratories, L.P. | $156.28 | 2023-2025 | Nemluvio, Aklief |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.43 | 2022-2025 | Spevigo |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $93.61 | 2023-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $83.65 | 2024-2025 | Siliq, Cabtreo |
| Organon LLC | $80.71 | 2024-2025 | Vtama |
| Almirall LLC | $69.77 | 2021-2023 | Seysara |
| Arcutis Biotherapeutics, INC. | $69.16 | 2023-2025 | Zoryve |
| Pfizer INC. | $57.92 | 2021-2023 | |
| Mayne Pharma Commercial LLC | $51.41 | 2022-2023 | |
| Leo Pharma INC. | $38.16 | 2024-2025 | Adbry |
| Botanix Sb INC | $30.31 | 2025 | Sofdra |
| Allergan, INC. | $27.24 | 2022 | |
| Mimedx Group, INC. | $17.42 | 2025 | |
| Genentech USA, INC. | $16.11 | 2023 | Xolair |
| Verrica Pharmaceuticals INC. | $16.05 | 2024 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kirsten Dickinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.